Bio/Pharma News

Mar 09, 2018
Pharmaceutical Technology
By Pharmaceutical Technology Editors
The European Medicines Agency has called for the immediate suspension and recall of AbbVie and Biogen's multiple sclerosis drug Zinbryta (daclizumab beta).
Mar 08, 2018
By Pharmaceutical Technology Editors
Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.
Mar 06, 2018
By Pharmaceutical Technology Editors
The companies will join forces to develop next-generation ex vivo cell therapies in oncology.
Mar 06, 2018
By Pharmaceutical Technology Editors
The companies will work together to develop prescription digital therapeutics for patients with schizophrenia and multiple sclerosis.
Mar 06, 2018
By Pharmaceutical Technology Editors
The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.
Feb 28, 2018
By Pharmaceutical Technology Editors
A jury verdict requiring Gilead Sciences to pay $2.54 billion for patent infringement to competitor Merck & Co. over Gilead's Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir), two best-selling hepatitis C drugs, has been overturned.
Feb 28, 2018
By Pharmaceutical Technology Editors
GlaxoSmithKline has issued a voluntary recall of three lots of respiratory inhalers in the United Kingdom, including preventer and emergency relief inhalers.
Feb 28, 2018
By Pharmaceutical Technology Editors
Merck & Co. has acquired oncology-focused biopharmaceutical company Viralytics to strengthen Merck's oncology pipeline.
Feb 27, 2018
By Pharmaceutical Technology Editors
Roche will acquire oncology-focused healthcare technology and services company Flatiron Health for $1.9 billion to further its personalized oncological healthcare strategy.
Feb 21, 2018
By Pharmaceutical Technology Editors
The companies have partnered to develop and commercialize vectorized antibodies against tau for Alzheimer's and other neurodegenerative diseases.
native1_300x100
lorem ipsum